UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)

Annals of oncology, 2013-04, Vol.24 (4), p.965-973

2013

Volltextzugriff (PDF)

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies

British journal of cancer, 2013-03, Vol.108 (4), p.762-765

2013

Volltextzugriff (PDF)

Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group’s Study E1203

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.4143-4143

2006

Volltextzugriff (PDF)

Long-term survival after locoregional therapy in patients with unresectable hepatocellular carcinoma: Improvements over two decades

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e14559-e14559

2010

Volltextzugriff (PDF)

Locoregional therapies as a bridge to transplant in patients with hepatocellular carcinoma

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e15608-e15608

2009

Volltextzugriff (PDF)

Drug eluting beads versus conventional TACE for unresectable hepatocellular carcinoma: Survival benefits and safety

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.4524-4524

2009

Volltextzugriff (PDF)

MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3013-3013

2011

Volltextzugriff (PDF)

Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.5589-5589

2010

Volltextzugriff (PDF)

Chemoembolization with doxorubicin drug-eluting beads for unresectable hepatocelluar carcinoma with portal vein thrombosis

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e14638-e14638

2010

Volltextzugriff (PDF)

Single-fraction image-guided extracranial radiosurgery for recurrent and metastatic abdominal cancers: Short-term local control, metabolic response, and toxicity

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.15597-15597

2008

Volltextzugriff (PDF)

Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and skin

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.2562-2562

2009

Volltextzugriff (PDF)

Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2538-2538

2010

Volltextzugriff (PDF)

Bortezomib (B) and doxorubicin (dox) in patients (pts) with hepatocellular cancer (HCC): A phase II trial of the Eastern Cooperative Oncology Group (ECOG 6202) with laboratory correlates

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.4592-4592

2008

Volltextzugriff (PDF)

Research participants’ views of nontherapeutic biopsies

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.13529-13529

2008

Volltextzugriff (PDF)

Building a culture of health through research: The role of the physical activity research center

Preventive medicine, 2020-01, Vol.130, p.105894-105894, Article 105894

Kauh, Tina J.

2020

Volltextzugriff (PDF)

The Critical Role of Racial/Ethnic Data Disaggregation for Health Equity

Population research and policy review, 2021-02, Vol.40 (1), p.1-7

2021

Volltextzugriff (PDF)

Teprotumumab, an IGF-1R Blocking Monoclonal Antibody Inhibits TSH and IGF-1 Action in Fibrocytes

The journal of clinical endocrinology and metabolism, 2014-09, Vol.99 (9), p.E1635-E1640

2014

Volltextzugriff (PDF)

Mentoring in Schools: An Impact Study of Big Brothers Big Sisters School-Based Mentoring

Child development, 2011-01, Vol.82 (1), p.346-361

2011

Volltextzugriff (PDF)

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

Clinical cancer research, 2016-02, Vol.22 (4), p.847-857

2016

Volltextzugriff (PDF)

Demonstrating Equity Through the Convening of Expert Panels

Big data, 2022-09, Vol.10 (S1), p.S15-S18

2022

Volltextzugriff (PDF)

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

Circulation (New York, N.Y.), 2023-07, Vol.148 (2), p.144-158

2023

Volltextzugriff (PDF)

Building an Equitable Future Through Data Disaggregation

Health equity, 2023-04, Vol.7 (1), p.251-260

2023

Volltextzugriff (PDF)

LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial

Investigational new drugs, 2021-08, Vol.39 (4), p.1057-1071

2021

Volltextzugriff (PDF)

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial

Journal of clinical oncology, 2016-05, Vol.34 (13), p.1500-1509

2016

Volltextzugriff (PDF)

Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma

Journal of vascular and interventional radiology, 2013-03, Vol.24 (3), p.307-315

2013

Volltextzugriff (PDF)

1 – 25 von 156

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(137)
Mit Volltextzugriff
(99)

Publikationsform

Sprache

Englisch
(156)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies

Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group’s Study E1203

Long-term survival after locoregional therapy in patients with unresectable hepatocellular carcinoma: Improvements over two decades

Locoregional therapies as a bridge to transplant in patients with hepatocellular carcinoma

Drug eluting beads versus conventional TACE for unresectable hepatocellular carcinoma: Survival benefits and safety

MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules

Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer

Chemoembolization with doxorubicin drug-eluting beads for unresectable hepatocelluar carcinoma with portal vein thrombosis

Single-fraction image-guided extracranial radiosurgery for recurrent and metastatic abdominal cancers: Short-term local control, metabolic response, and toxicity

Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and skin

Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors

Bortezomib (B) and doxorubicin (dox) in patients (pts) with hepatocellular cancer (HCC): A phase II trial of the Eastern Cooperative Oncology Group (ECOG 6202) with laboratory correlates

Research participants’ views of nontherapeutic biopsies

Building a culture of health through research: The role of the physical activity research center

The Critical Role of Racial/Ethnic Data Disaggregation for Health Equity

Teprotumumab, an IGF-1R Blocking Monoclonal Antibody Inhibits TSH and IGF-1 Action in Fibrocytes

Mentoring in Schools: An Impact Study of Big Brothers Big Sisters School-Based Mentoring

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

Demonstrating Equity Through the Convening of Expert Panels

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

Building an Equitable Future Through Data Disaggregation

LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial

Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma

Suchergebnisse filtern